MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- UNICHEM LABORATORIES LIMITED (pharmaceuticals)
- Latest 8 Quarter Result
Unichem Lab Quarterly Results 
(UNCHM)
Here are the latest quarterly results of Unichem Lab. For more details, see the Unichem Lab financial fact sheet and Unichem Lab share price and chart. For a sector overview, read our pharmaceuticals sector report.
Unichem Lab Quarterly Results
| No. of Mths Qtr. Ending |
3
Mar-17 |
3
Jun-17 |
3
Sep-17 |
3
Dec-17 |
3
Mar-18 |
3
Jun-18 |
3
Sep-18 |
3
Dec-18 |
8-Qtr Chart Click to enlarge |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 3,439 | 3,141 | 4,281 | 1,591 | 2,051 | 2,014 | 2,459 | 2,448 | |
| Other income | Rs m | 1 | 82 | 69 | 67 | 454 | 193 | 326 | 276 | |
| Turnover | Rs m | 3,440 | 3,223 | 4,350 | 1,658 | 2,505 | 2,207 | 2,785 | 2,723 | |
| Expenses | Rs m | 3,102 | 3,143 | 3,558 | 2,142 | 2,311 | 2,401 | 2,441 | 2,644 | |
| Gross profit | Rs m | 337 | -2 | 723 | -551 | -260 | -387 | 18 | -196 | |
| Depreciation | Rs m | 104 | 104 | 112 | 115 | 128 | 123 | 148 | 168 | |
| Interest | Rs m | 3 | 7 | 11 | 9 | 5 | 0 | 1 | 1 | |
| Profit before tax | Rs m | 231 | -31 | 669 | -608 | 62 | -317 | 195 | -90 | |
| Tax | Rs m | -84 | -45 | 211 | -29 | 34 | -110 | 18 | -153 | |
| Profit after tax | Rs m | 315 | 15 | 458 | -580 | 28 | -207 | 177 | 63 | |
| Gross profit margin | % | 9.8 | -0.1 | 16.9 | -34.6 | -12.7 | -19.2 | 0.7 | -8.0 | |
| Effective tax rate | % | -36.5 | 149.0 | 31.5 | 4.7 | 54.6 | 34.8 | 9.4 | 170.1 | |
| Net profit margin | % | 9.1 | 0.5 | 10.7 | -36.4 | 1.4 | -10.3 | 7.2 | 2.6 | |
| Diluted EPS | Rs | 3.5 | 0.2 | 5.1 | -6.4 | 0.3 | -2.3 | 1.9 | 0.7 | |
| Diluted EPS (TTM) | Rs | 11.5 | 8.8 | 11.6 | 2.3 | -0.9 | -3.3 | -6.4 | 0.7 | |
 Subscriber Feature |
||||||||||
Interim results exclude extraordinary / exceptional items
Read: Unichem Lab 3QFY19 Result Performance Review
More Pharmaceuticals Company Quarterly Results: SANOFI INDIA PANACEA BIOTECH INDOCO REMEDIES TORRENT PHARMA ORCHID PHARMA LTD
Compare UNICHEM LAB With: SANOFI INDIA PANACEA BIOTECH INDOCO REMEDIES TORRENT PHARMA ORCHID PHARMA LTD
Compare UNICHEM LAB With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends Marginally Higher; Realty and Energy Stocks Witness Buying(Closing)
Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector.
Views on news
UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)
Feb 4, 2019 | Updated on Feb 4, 2019For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.
UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)
Nov 5, 2018 | Updated on Nov 5, 2018For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)
Mar 8, 2019History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?
Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)
Mar 7, 2019Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...
The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)
Mar 7, 2019India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?
Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)
Mar 6, 2019Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?
The Jet Airways Crisis in 6 Charts(Sector Info)
Mar 5, 2019What happened to Jet Airways, once among top 3 airlines in India? Is it another Kingfisher in the making? Read on...
More|
| |
UNICHEM LAB SHARE PRICE
Mar 18, 2019 (Close)
TRACK UNICHEM LAB
- Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON UNICHEM LAB
UNICHEM LAB - ORCHID PHARMA LTD COMPARISON
COMPARE UNICHEM LAB WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.